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Prostate cancerThe cyclic AMP phosphodiesterases type 4 (PDE4s) are expressed in a cell speciﬁc manner, with
intracellular targeting directed by unique N-terminal anchor domains. All long form PDE4s are
phosphorylated and activated by PKA phosphorylation within their upstream conserved region 1
(UCR1). Here, we identify and characterise a novel PKA site (serine 42) within the N-terminal region
of PDE4D7, an isoform whose activity is known to be important in prostate cancer progression and
ischemic stroke. In contrast to the UCR1 site, PKA phosphorylation of the PDE4D7 N-terminus
appears to occur constitutively and inhibits PDE4 activity to allow cAMP signalling under basal
conditions.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).1. Introduction
30,50-cyclic adenosine monophosphate (cAMP) is a ubiquitous
intracellular second messenger that acts to orchestrate a number
of important physiological functions that are triggered by activa-
tion of speciﬁc cell-surface receptors. Speciﬁcity of receptor action
is often underpinned by the compartmentalisation of intermedi-
ates within the cAMP-signalling cascade. Discrete positioning of
enzymes that synthesise cAMP (adenylate cyclase), are activated
by cAMP (PKA, EPAC and cyclic nucleotide – gated ion channels)
or degrade the second messenger (phosphodiesterases) allow the
cell to tailor cellular responses following signals generated by a
number of receptors coupled to Gas [1]. The duration and strength
of signals produced by cAMP effectors is often heavily inﬂuenced
by action of a super-family of enzymes that has evolved to degrade
cyclic-nucleotides, the phosphodiesterases (PDEs) [2].
Of particular interest is the PDE4 family of enzymes, which is
made up of over 25 different isoforms, many of which have
important, non-redundant functions [3]. Often, the function of a
particular PDE4 isoform is conferred by its unique N-terminal,
which acts as a ‘‘postcode’’ to anchor PDE4 enzymes to discreteintracellular domains where they sculpt signal-speciﬁc cAMP gra-
dients. PDE4s also contain a catalytic unit and regulatory domains
termed ‘‘upstream conserved regions one and two’’ (UCR1/2)
which are highly conserved throughout the isoforms [4]. All
long-form PDE4s contain UCR1, which contains a PKA motif that
becomes phosphorylated during conditions of raised cAMP [5].
Such an action serves to activate PDE4 and rapidly reduce the local
concentration of cAMP. This feedback loop underpins the transient
nature of cAMP signals and ensures a rapid but ﬂeeting response to
activation of Gas-coupled receptors [6].
In addition to phosphorylation of UCR1, the long isoform
PDE4D3 undergoes PKA phosphorylation within its unique N ter-
minus [5]. This modiﬁcation does not affect activity but instead
increases the afﬁnity of binding to the A-kinase anchor protein,
mAKAP [7]. To date, this is the only known case of a long PDE iso-
form being phosphorylated by PKA other than within its UCR1
domain. Using peptide array technology and a novel phospho-
speciﬁc antibody, we demonstrate that PDE4D7, an isoform who’s
activity is known to be important in prostate cancer progression
[8] and ischemic stroke [9], is also phosphorylated by PKA within
its unique N terminus on serine 42. We show modiﬁcation of
PDE4D7 in this way occurs under basal conditions, reduces
PDE4D7 activity, and we hypothesise that this feature allows basal
cAMP signalling, which may be necessary for cellular homeostasis
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tate cancer from the androgen sensitive to androgen insensitive
state.
2. Materials and methods
2.1. Reagents
Forskolin (Sigma) and KT5720 (Enzo) were dissolved in
dimethyl sulfoxide. Anti-PKA phospho substrate (RXXpS) antibody
was supplied from Cell Signalling, USA: Cat. No. 9621. Anti-
phospho PDE4D7-serine42 antibody was custom made by AMSBIO
(Europe) in rabbits against a phosphorylated peptide correspond-
ing to residues 34EPYLVRRL(p)SCRN45. Total PDE4D7 antibody
was custom made by Altabioscience (UK) against a GST-fusion of
the whole unique N terminal region of PDE4D7.
2.2. Peptide array
Peptide libraries were produced by automatic SPOT synthesis
and synthesized on continuous cellulose membrane supports on
Whatman 50 cellulose membranes using Fmoc-chemistry with
the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments
AG, Köln, Germany) as previously described by us [10]. PKA
phosphorylation of an immobilized library of PDE4D7 peptides
was undertaken using 100 units of puriﬁed PKA catalytic subunit
(Promega). Recombinant kinase was diluted in phosphorylation
buffer (20 mM Tris–HCl; pH 7.5, 10 mM MgCl2, 0.5 mM CaCl2,
1 mM DTT, 0.2 mg/ml BSA, 1 mM ATP) and incubated with arrays
at 30 C for 30 min with shaking.
2.3. Site directed mutagenesis of PDE4D7
Site-directed mutagenesis was performed using the Quick-
change kit (Stratagene) according to manufacturer’s instructions.
The following primers were used to create the required full length
and N terminal mutants. PDE4D7 S42A mutant, forward primer:
AGACTTGCATGTCGCAATATTCAGCTTCCCCCTCTC, reverse primer:
ATTGCGACATGCAAGTCTCCGGACAAGATAGGGTTCCATTCC. S42D
mutant, forward primer: CGGAGACTTGACTGTCGCAATATTCAGC-
TTCCCCCTCTC, reverse primer: GGGATAGAACAGGCCTCTGAACT-
GACAGCGTTATAAGTCG.
2.4. Puriﬁcation of GST-PDE4D7
Brieﬂy; BL21 cells were transformed with the fusion protein and
induction was brought about by addition of 1 mM of isopropyl-b-D-
thiogalactopyranoside (IPTG). Following protein induction, cells
were lysed by sonication and lysate was incubated with
Glutathione Sepharose beads (Amersham). Following an incuba-
tion period, the beads were washed in elution buffer (50 mM Tris
pH 8.0) + glutathione (6.8 mg of reduced glutathione (Sigma) per
1 ml of elution buffer). The beads were pelleted by brief centrifuga-
tion and the eluate was collected. Overnight dialysis of the collect-
ed eluate was carried out in dialysis buffer (100 mM NaCl, 50 mM
Tris–HCl; pH 8.0, 5% glycerol, 5 mM DTT) in slide-a-lyzer cassettes
(Piercenet) at 4 C to remove any detergents or glutathione.
Following recovery of the eluates from the cassettes, the protein
concentration was determined by a Bradford assay.
2.5. In vitro PKA phosphorylation of PDE4D7
Puriﬁed (2 lg) wt GST-PDE4D7 unique N terminal region and
S42A wt GST-PDE4D7 unique N terminal region (Fig. 1E/F) or
VSV-pull downs of Wt, S42A and S42D transfections (Fig. 3C) were
incubated with 25 units of puriﬁed PKA catalytic subunit(Promega) in phosphorylation buffer (20 mM Tris–HCl; pH 7.5,
10 mM MgCl2, 0.5 mM CaCl2, 1 mM DTT, 0.2 mg/ml BSA, 1 mM
ATP) for 1 h at 30 C with gentle agitation. The samples were run
on an SDS–PAGE gel and immunoblotted with the PKA phospho-
substrate and phospho-speciﬁc antibodies.
2.6. Cellular transfection of wt and mutant PDE4D7 constructs and cell
treatments
VSV tagged wild type PDE4D7, S42A PDE4D7, S42D PDE4D7 and
dnPDE4D7 were transfected into HEK293 cells using Polyfect
transfection reagent (Qiagen). Cells were treated with KT5720
(4 lM) for 20 min prior to forskolin (100 lM) treatment for the
time points indicated, or forskolin alone (100 lM). Control cells
were treated with DMSO or left untreated (NT). Cell lysates were
harvested in KHEM buffer (50 mM HEPES pH 7.4, 50 mM KCL,
1.92 mM MgCl2) (for PDE activity assays) or 3T3 lysis buffer
(25 mM HEPES, 10% w/v glycerol, 50 mM NaCl, 1% w/v
Triton  100, 50 mM NaF, 30 mM NaPP, 5 mM EDTA, pH7.4) con-
taining Complete, EDTA-free Protease Inhibitor Cocktail Tablets
(Roche) and PhosStop Phosphatase Inhibitor Cocktail Tablets
(Roche).
2.7. Phosphodiesterase activity assays
Phosphodiesterase activity was measured using a radioactive
cAMP hydrolysis assay that has been described previously [5].
[8-3H] adenosine cyclic-30,50-mono-phosphate was sourced from
Amersham Biosciences (Little Chalfont, UK) and cyclic-30,50-
mono-phosphate from Sigma. The substrate concentration used
for PDE assays was 150 nM, and the speciﬁc PDE activity was
determined as pmol cAMP hydrolysed/min/mg protein. PDE activ-
ities were then normalised for expression of construct, and the
data were normalised to untreated (NT) wild type PDE4D7 activity.
3. Results
Sequence analysis of the PDE4D7 sequence uncovered a novel,
putative consensus PKA site in the unique N-terminal region
(37LVRRLSCR44) in addition to the already known site in UCR1
(125QRRESFL131) (Fig. 1A). To determine whether the 4D7 N-terminal
motif is a PKA substrate, immobilised peptide array libraries of the
N-terminal and UCR1 regions were synthesised using peptide
array. Peptide array has been used by our group to successfully
identify ubiquitination [11] and SUMOylation [12] sites on
PDE4D5, and PKA sites on PDE8 [13], PI3K [14] and DNAPK [15].
Peptide arrays of overlapping 25-mer peptides, sequentially shifted
by 5 amino acids and spanning the PDE4D7 N-terminal and UCR1
regions were incubated with a PKA assay mix before detection of
phosphorylation using a PKA phospho-substrate antibody
(Fig. 1B). Only two regions of phosphorylation were detected and
these contained the previously known PKA site in UCR1
(125QRRESF130) and the new site in the unique N-terminal
(38VRRLSC43) (Fig. 1B). No phosphorylation was detected when
active PKA was omitted from the assay mix (Fig. 1C left panel)
and peptide spotting was veriﬁed by coomassie staining (Fig. 1C
right panel). In addition to the PKA phospho-substrate antibody,
phosphorylation of serine 42 by PKA on peptide array was also
be detected by a novel phospho-speciﬁc antibody raised against a
peptide containing a phosphorylated version of the 4D7 N-termi-
nal PKA site. (Fig. 1D, right panel). No such phosphorylation was
detected by pre-immune serum or when PKA catalytic subunit
was omitted from the assay mix (Fig. 1D left and middle panels).
Wild type N-terminal GST-PDE4D7 (WT-NT) and mutant
N-terminal GST-PDE4D7-S42A (S42A-NT) were puriﬁed (Fig. 1E)
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Fig. 1. (A) Schematic depicting the domain structure of PDE4D7 including isoform speciﬁc N-terminal region (N-term), upstream conserved regions 1 and 2 (UCR1/2) and the
catalytic region. (B) Peptide arrays containing immobilised peptides corresponding to the regions of the PDE4D7 N-terminal and UCR1 were subjected to phosphorylation
following incubation with the PKA catalytic subunit. Phosphorylation (dark spots) was detected using a phospho-PKA substrate antibody. (C) Controls for the experiment
described in B. The experiment was conducted without the catalytic subunit of PKA (left panel) and the presence of peptides was detected using Coomassie (right panel). (D)
Validation of a novel Serine 42 phospho-speciﬁc antibody. The serine 42 phospho-speciﬁc antibody (right panel) or pre-immune serum (left panel) was used to detect
phosphorylated peptides on peptide arrays corresponding to the PDE4D7 N-terminal. An experimental control conducted without the catalytic subunit of PKA was also
undertaken (middle panel). (E) GST-fusion constructs (wild type and S42A) corresponding to the N-terminal region of PDE4D7 were puriﬁed and (F) used in a phosphorylation
assay conducted with the catalytic subunit of PKA. The phosphorylation of GST-fusion constructs was detected using the serine 42 phospho-speciﬁc antibody or phospho-PKA
substrate antibody. All data in Fig. 1 typical of n = 3.
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catalytic unit. Phosphorylation of the serine 42 site in the wild type
N-terminal construct was detected by the PKA phospho-substrate
antibody and our phospho-speciﬁc S42 antibody (Fig. 1F). Howev-
er, neither picked up phosphorylation in the S42A mutants
(Fig. 1F). Gratifyingly, the PKA phospho-substrate antibody also
detected auto-phosphorylation of the PKA catalytic unit (Fig. 1F,
upper panel, upper band), whereas phospho-speciﬁc S42 antibody
did not.
To determine whether PKA phosphorylation of PDE4D7 at ser-
ine 42 could occur in a cellular context, HEK293 cells were trans-
fected with VSV-tagged constructs of wild type PDE4D7 and the
mutants S42A and S42D. Cells were left untreated or pre-treated
with the PKA inhibitor KT5720, before endogenous cAMP levels
were elevated using the adenylate cyclase activator forskolin. Cell
lysates were then probed with our phospho-speciﬁc S42 antibody
and an antibody against VSV to evaluate protein loading and con-
struct expression (Fig. 2A). Basal levels of S42 phosphorylation
could be detected and these were signiﬁcantly increased following
forskolin treatment. The forskolin-induced increase in phosphory-
lation was attenuated in KT pre-treated cells, indicating that PKAwas the kinase responsible (Fig. 2A). No phosphorylation of
PDE4D7 S42 was detected in cells expressing the S42A or S42D
mutant. A forskolin time course showed that S42 phosphorylation
steadily increased up to 20 min (Fig. 2B, upper panel and right pan-
el). As expected, no phosphorylation of the S42A PDE4D7 mutant
could be detected. To show that forskolin was active throughout
the time course, PKA phosphorylation of non-speciﬁed substrates
could be seen using the PKA phospho-substrate antibody (Fig. 2B,
middle panel). Interestingly, a mutant of PDE4D7 carrying a single
substitution that renders the enzyme completely inactive, resulted
in a more robust and sustained phosphorylation of S42 (Fig. 2C).
Presumably, this is because the ‘‘dead’’ enzyme has lost the ability
to inﬂuence local cAMP concentration around it, leading to unfet-
tered phosphorylation by PKA. As PDE4D7 activity is signiﬁcantly
down-regulated between androgen sensitive and androgen insen-
sitive prostate cancer, and has been shown to mediate androgen
sensitive prostate cancer cell proliferation [8], we were keen to
determine if the phosphorylation of PDE4D7 could be observed
in the androgen sensitive prostate cancer cell lines DuCaP and
VCaP. Basal S42 phosphorylation was detected in both lines and
this was increased following forskolin treatment and blocked by
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Fig. 2. (A) HEK293 cells were transfected with VSV-tagged PDE4D7 wild type or the
S42A or S42D mutants and treated with Forskolin or Forskolin after a pretreatment
with the PKA inhibitor KT5720. Cellular lysates were blotted with serine 42
phospho-speciﬁc antibody or VSV antibody. Quantiﬁcations on right panel,
⁄ = P < 0.05. (B) HEK293 cells were transfected with VSV-tagged PDE4D7 wild type
or the S42A mutant and treated with Forskolin over 20 min. Cellular lysates were
blotted with serine 42 phospho-speciﬁc antibody or phospho-PKA substrate
antibody or VSV antibody. Quantiﬁcations on right panel, ⁄ = P < 0.05. (C) HEK293
cells were transfected with VSV-tagged PDE4D7 wild type or the dominant
negative, catalytically inactive mutant (D/N) and treated with Forskolin over
20 min. Cellular lysates were blotted with serine 42 phospho-speciﬁc antibody or
VSV antibody. (D) DuCaP and VCaP cells and treated with Forskolin or Forskolin
after a pretreatment with the PKA inhibitor KT5720. Cellular lysates were blotted
with Serine 24 phospho-speciﬁc antibody orPDE4D7 antibody. (E) DuCaP and VCaP
cells were treated with Forskolin over 20 min. Cellular lysates were blotted with
serine 42 phospho-speciﬁc antibody or PDE4D7 antibody or GAPDH antibody. All
data in Fig. 2 typical of n = 3.
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Fig. 3. (A) HEK293 cells were transfected with VSV-tagged PDE4D7 wild type or the
S42A or S42D mutants and treated with Forskolin. Cellular lysates were blotted for
VSV or GAPDH. The PDE activity of cellular lysates was determined and expressed
as a percentage of wild type control. ANOVA was used to determine signiﬁcance of
change (n = 3). (B) HEK293 cells were transfected with VSV-tagged PDE4D7 wild
type or the S42A or S42D mutants and treated with Forskolin over a 20 min time
course. Cellular lysates were blotted with serine 42 phospho-speciﬁc antibody or
VSV antibody or a phospho-UCR1 (S129) antibody. Data typical of n = 3. (C) VSV-
tagged PDE4D7 wild type or the S42A or S42D mutants were pulled down from
transfected HEK293 and subjected to phosphorylation by PKA catalytic unit. Ips
were blotted with a phospho-UCR1 (S129) antibody or VSV. Data for each of three
replicates is shown.
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pressed PDE4D7 (Fig. 2B), endogenous PDE4D7 in DuCaP (Fig. 2E,
upper panel) and VCaP cells (Fig. 2E, lower panel) became
phosphorylated on S42 gradually following forskolin treatment
(Fig. 2E).
As all long form PDE4 isozymes are activated following PKA
phosphorylation of their UCR1 domain [5], creating a feedback loop
to bring about cessation of cAMP signalling events, we were inter-
ested to see if N-terminal phosphorylation affected PDE4D7 activ-
ity. Lysates isolated from HEK293 cells, which had been transfected
with VSV-tagged WT or mutant PDE4D7 constructs, were assayed
for PDE activity, following 5 min forskolin challenge. Transfection
efﬁciency was evaluated byWestern blotting (Fig. 3A, lower panel).
As expected, WT PDE4D7 doubled in activity after forskolin treat-
ment (Fig. 3A, bar chart). Interestingly, the phospho-resistant
S42A mutant exhibited an active phenotype with increased basal
activity compared to wtPDE4D7 of >170% (p = 0.03, ANOVA) and
forskolin challenge did not further increase its activity (Fig. 3A,
bar chart). The phospho-mimetic S42D mutant, on the other hand,showed a small non-signiﬁcant increase in basal activity compared
to WT PDE4D7 NT (36%). The activity of this mutant was increased
to a similar extent as WT PDE4D7 following forskolin challenge.
We suggest that the hyperactivity associated with the S42A
mutant is a result of the fact that phosphorylation of this site
provides a mode of negative regulation for PDE4D7, ablation of
which leads to activation. It is noteworthy that this site is basally
phosphorylated in all of the cell lines investigated here, implying
that the cell may require an inactive form of PDE4D7 for normal
cellular homeostasis. We were unable to recreate phosphoryla-
tion-dependent enzyme inhibition at this site with the phospho-
mimic mutant S42D. It behaved in a similar way to WT PDE4D7
under both basal conditions and forskolin treatment (Fig. 3A, bar
chart), suggesting that the negative charge introduced by the
substitution was not sufﬁcient to evoke a functional change.
Since ablation of Ser42 phosphorylation led to a more active
form of PDE4D7, we decided to determine whether this would
impinge on the phospho-dynamics of the UCR1 site. Lysates pre-
pared from cells overexpressing WT PDE4D7 and the S42A, S42D
754 A.M. Byrne et al. / FEBS Letters 589 (2015) 750–755mutants were immunoblotted for phospho-UCR1 and phospho-
Ser42. In support of the notion that blockade of the S42 phospho-
site increases enzymatic activity, very little phosphorylation of
UCR1 could be detected in the S42A mutant, even after 20 min
forskolin treatment (Fig. 3B, upper panel). Presumably, the increase
in PDE4 activity conferred by this mutation, acts to diminish local
cAMP concentrations, in turn, attenuating PKA activity and pre-
venting phosphorylation at the UCR1 PKA site, though it is possible
that S42A directly affects the phosphorylation of UCR1 by PKA as
isolated VSV Ips of the S42A mutant did not get phosphorylated
by active PKA catalytic subunit, whereas wild type and S42D
mutant did (Fig. 3C).
As with activity measurements, the WT PDE4D7 and S42D
mutant behaved in a similar fashion with respect to UCR1
phosphorylation suggesting that the substitution of a negatively
charged amino acid at S42 did not mimic the phosphorylation. In
both cases (WT PDE4D7 and S42D mutant), no basal UCR1 phos-
phorylation could be detected, with a sustained phosphorylation
being triggered by forskolin.
4. Discussion
Fine control of compartmentalised cAMP signalling is under-
pinned by the discrete positioning of phosphodiesterase enzymes
which act to both maintain basal cAMP concentrations and shape
cAMP gradients following activation of cell surface receptors [1].
Aberrant signalling within the cAMP signalling system has been
closely linked with prostate cancer progression [16]. Changes in
adenylate cyclase activity [17], PKA catalytic subunit expression
[18] and most recently PDE4 expression [8] have all been observed
between androgen-sensitive and androgen independent cancer
phenotypes. In the latter case, transcripts from three sub-families
(PDE4A, PDE4B and PDE4D) were detected, with PDE4D being the
most highly expressed. Separation of a range of prostate cancer
models and xenografts into androgen sensitive and androgen inde-
pendent categories showed that PDE4D isoforms were down-
regulated in the androgen independent prostate cancer models.
PDE4 isoform proﬁling identiﬁed PDE4D7 as the most important
PDE4 isoform in the regulation of prostate cancer growth with high
expression in androgen sensitive cells and a dramatic decline into
androgen insensitivity [8]. Inhibition of a PDE4D7 pool sequestered
to a sub-plasma membrane compartment increased prostate
cancer cell proliferation and PDE4D7 has now been proposed as a
novel biomarker for diagnosis of the AI prostate cancer phenotype.
Investigation into the mechanism behind PDE4D7 expression
changes in prostate cancer cell lines demonstrated that transcrip-
tion from the PDE4D7 locus was not directly controlled by the
androgen receptor [8] and further studies are required to elucidate
the molecular events leading to changes in cellular PDE4D7 levels.
In this paper we provide evidence of a novel PKA phosphoryla-
tion site on PDE4D7 that alters its activity. Blockade of the phos-
phorylation of PDE4D7 on serine 42 dramatically increases its
activity suggesting that phosphorylation at this site serves to inhi-
bit the enzyme. Interestingly, the phosphorylation of PDE4D7 on
serine 42 can be detected in the prostate cancer cell lines DuCaP
and VCaP opening up the possibility that this post-translational
modiﬁcation may further promote the proliferative signalling
observed following a reduction in PDE4D7 activity. Presumably,
the increases in cAMP caused by this event could contribute to
the AI phenotype by over exciting the autocrine and paracrine sig-
nalling systems that support androgen receptor transactivation
[19]. More speciﬁcally, it is likely that membrane bound PDE4D7
regulates the cAMP gradients that are formed following activation
of various Gas coupled receptors, which are known to signal partly
through transactivation of the androgen receptor [20]. Recent
reports of PDE4B knockdown following oxidative stress challengehave also been shown to promote growth of castration-resistant
prostate cancer cells [21]. Experiments using our phospho-serine
42 speciﬁc antibody to screen AS and AI cell lines and xenografts
may shed more light on the possible importance of PDE4D7
phosphorylation as an contributing event in the molecular pathol-
ogy of prostate cancer.
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